Biotechnology company, Prothena, has announced positive topline P1 SAD study results for PRX005, an investigational tri-epitopic antibody for the treatment of Alzheimer’s disease.
In a simulation model, lecanemab treatment was estimated to potentially slow the rate of disease progression, maintaining treated patients for a longer duration in earlier stages of mild cognitive impairment (MCI) due to early AD.
Prothena has announced FDA clearance of IND for PRX012, a subcutaneous anti-amyloid beta antibody under investigation for the treatment of Alzheimer’s disease (AD).
LEXEO Therapeutics, a clinical-stage gene therapy company, is partnering with CDMO, Fujifilm Diosynth Biotechnologies (FDB), to support the development and manufacturing of its AAV-mediated gene therapies.